EQS-News

LPKF Laser & Electronics SE: LPKF significantly increases revenue and earnings in the 2022 financial year - Seite 2

2022 was Dr Klaus Fiedler's first year as CEO at the head of the technology company. Fiedler is enthusiastic about the company's innovative strength. "Our employees have the creativity, experience and courage to develop highly exciting, disruptive technologies. I strongly support that." Together with CFO Christian Witt, Fiedler has defined a clear strategic agenda for the LPKF Group: "The core business will be consistently focused on growth markets. At the same time, we are actively driving forward our disruptive technologies and are specifically addressing strongly growing markets such as semiconductors, displays and biotechnology".

Business development in the individual segments varied significantly in the 2022 financial year. "While we were able to achieve record figures in some business segments, others were not satisfactory in terms of revenue and earnings development, and we have initiated corresponding measures," says Christian Witt, LPKF's Chief Financial Officer since 2018. "In addition, we will drive scalability and the use of Group-wide synergies, thereby increasing profitability in the Group in the medium term," adds Witt.

In its core business, the solar sector is benefiting strongly from the global efforts to reduce CO2 emissions and the energy crisis, both leading to a shift towards renewable energies. Overall, revenue in solar systems more than tripled to EUR 38 million in 2022. LPKF is well positioned in the market for thin-film solar technology, has expanded its customer base globally and has also won its first major orders for the next technology generation.

The LIDE technology for precision glass structuring is one of the company’s strategic growth initiatives.  Although LIDE is still in an early phase of market penetration, renowned technology leaders are increasingly opting for this disruptive production process.

LPKF's ARRALYZE technology addresses the life science market and provides a complete solution to the need for scalable single cell screening for high-growth applications such as cancer therapies and personalized medicine. In the first half of 2023, the company is delivering systems to Beta customers in academia. From the second half of the year, the first ARRALYZE systems will be available for purchase.